GLOBAL NETWORK
We continue to build our infrastructure so that we will be able to quickly bring both marketed products and future products now in clinical development to patients around the world. We have made much progress establishing integrated operations, including increased direct sales, in Russia, eastern Europe, China, South Africa, the Middle East, and Southeast Asia. Integrated operations make a significant contribution to the company's growth, as the strong performance of a number of western European countries has consistently shown.
MANUFACTURING AND DISTRIBUTION
We invest in manufacturing infrastructure to enable us to manage our supply chain, support the development and launch of new products, and ensure that products reach patients around the world. Our Waterford, Ireland, plant received approval for the finishing and packaging operations for Thymoglobulin in 2006 and for Cerezyme in early 2007; we expect similar approval for Myozyme in 2007. We are also expanding tableting and bottling operations for Renagel and Renvela at Waterford, with a second building anticipated to come online in late 2007. At our Geel, Belgium, protein manufacturing plant, we completed engineering runs of Campath in 2006 and plan to follow with Myozyme in 2007. We will also begin expansion of plants in the United Kingdom, France, Massachusetts, and New Jersey.
CLINICAL AND REGULATORY AFFAIRS
Our ability to serve patients around the world depends on global clinical trials and regulatory filings. In 2006, we supported more than 100 clinical studies and 3,000 regulatory submissions. We also filed 28 marketing applications in new jurisdictions and had first-time approvals in multiple countries including Serbia, Montenegro, Ukraine, and India.
Genzyme has 73 locations in 32 countries, including 17 manufacturing facilities and 9 genetic testing laboratories. We have more than 750 employees in our worldwide clinical development group and regulatory affairs staff in more than 29 countries.
ANNUAL REPORT HOME
